Research programme: antibacterials - Evotec AG/GPC Biotech

Drug Profile

Research programme: antibacterials - Evotec AG/GPC Biotech

Latest Information Update: 27 Apr 2004

Price : $50

At a glance

  • Originator Evotec AG; GPC Biotech AG
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 27 Apr 2004 Discontinued - Preclinical for Bacterial infections in Germany (unspecified route)
  • 15 Mar 2004 No development reported - Preclinical for Bacterial infections in Germany (unspecified route)
  • 06 Apr 1999 Preclinical development for Bacterial infections in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top